Abstract
Background: Induction chemotherapy has become the standard of care for patients with locally advanced breast cancer (LABC) and currently is being evaluated in prospective clinical trials in patients with earlier-stage disease. To better gauge the role of axillary lymph node dissection in patients with LABC this study was performed to assess initial axillary status on physical and ultrasound examination, axillary tumor downstaging following induction chemotherapy, and the accuracy of physical examination compared with axillary sonography in predicting which patients will have axillary lymph node metastases found on pathologic examination.
Methods: Between 1992 and 1996, 147 consecutive patients with LABC were registered in a prospective trial of induction chemotherapy using 5-fluorouracil, doxorubicin, and cyclophosphamide. Physical and ultrasound examinations of the axilla were performed at diagnosis and after induction chemotherapy. Segmental resection with axillary lymph node dissection or modified radical mastectomy was performed, followed by postoperative chemotherapy and irradiation of the breast or chest wall and regional lymphatics.
Results: Following induction chemotherapy, 43 (32%) of the 133 patients with clinically positive lymph nodes on initial examination had axillary tumor downstaging as assessed by physical and ultrasound examination. The sensitivity of axillary sonography in identifying axillary metastases was significantly higher than that of physical examination (62% vs. 45%,P=.012). The specificity of physical examination (84%) was higher than that of sonography (70%), but the difference did not reach statistical significance. Among the 55 patients in whom the findings of both physical and ultrasound examination of the axilla were negative following induction chemotherapy, 29 patients (53%) were found to have axillary lymph node metastases on pathologic examination of the axillary contents. However, 28 (97%) of these patients had either 1 to 3 positive lymph nodes or only micrometastases 2 to 5 mm in diameter.
Conclusions: Preoperative clinical assessment of the axilla by physical examination combined with ultrasound examination is not completely accurate in predicting metastases in patients with LABC following tumor downstaging. However, patients with negative findings on both physical and ultrasound examinations of the axilla may be potential candidates for omission of axillary dissection if the axilla will be irradiated because minimal axillary disease remains. Patients who have positive findings on preoperative physical or ultrasound examinations should receive axillary dissection to ensure local control. A prospective randomized trial of axillary dissection versus axillary radiotherapy in patients with a clinically negative axilla following induction chemotherapy is currently underway.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998.CA Cancer J Clin 1998;48:6–29.
Zeichner GI, Mohar BA, Ramirez UMT. Epidemiologia del cancer de mama en el Instituto National de Cancerologia (1989–1993).Cancerologia 1993;39:1825.
Delena M, Zucali R, Viganotti G, Valagussa P, Bonadonna G. Combined chemotherapy-radiotherapy approach in locally advanced (T3b–T4) breast cancer.Cancer Chemother Pharmacol 1978;1:53–9.
Hortobagyi GN, Blumenschein GR, Spanos W, et al. Multimodal treatment of locoregionally advanced breast cancer.Cancer 1983;51:763–8.
Lippman ME, Sorace RA, Bagley CS, Danforth DW, Lichter A, Wesley MN. Treatment of locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery.NCI Monographs 1986;1:156–9.
Morrow M, Braverman A, Thelmo W, et al. Multimodal therapy for locally advanced breast cancer.Arch Surg 1986;121:1291–6.
Jacquillat CL, Baillet F, Weil M, et al. Results of conservative treatment combining induction (neoadjuvant) and consolidation chemotherapy, hormonotherapy, and external and interstitial irradiation in 98 patients with locally advanced breast cancer (IIIA–IIIB).Cancer 1988;61:1977–82.
Scholl SM, Fourquet A, Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6.Eur J Cancer 1994;5:645–52.
McCready DR, Hortobagyi GN, Kau SW, Smith TL, Balch CM. The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer.Arch Surg 1989;124:21–5.
Bonnadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more.J Natl Cancer Inst 1990;82:1539–45.
Schwartz GF, Birchansky CA, Komarnicky LT, et al. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast.Cancer 1994;73:362–9.
Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.J Clin Oncol 1997;15:2483–93.
Delena M, Varini M, Zucali R, et al. Multimodal treatment for locally advanced breast cancer.Cancer Clin Trials 1981;4:229–36.
Perloff M, Lesnick GJ, Korzun A, et al. Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: Cancer and Leukemia Group B study.J Clin Oncol 1988;6:261–9.
Rahman ZU, Frye DK, Buzdar AU, et al. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer.J Clin Oncol 1997;15:3171–7.
Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel, a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant breast cancer.J Clin Oncol 1995;13:2886–94.
Vermorken JB, ten Bokkel Huinink WW, Mandjes IA, et al. High dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: European cancer center trial.Semin Oncol 1995; 22(suppl 8):16–22.
Dhingra K, Singletary E, Strom E, et al. Randomized trial of G-CSF (Filgrastim)-supported dose-intensive neoadjuvant chemotherapy in locally advanced breast cancer.Proc Am Soc Clin Oncol 1995;14:94.
Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ.Manual for Staging of Cancer. 4th ed. Philadelphia: JB Lippincott, 1993;149.
Altman DG.Some Common Problems in Medical Research (Practical Statistics for Medical Research). London: Chapman and Hall, 1995.
Fisher B, Wolmark N, Bauer M, Redmond C, Gebhardt M. The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast.Surg Gynecol Obstet 1981;152:763–72.
Bruneton JN, Caramella E, Hery M, Aubanel D, Manzino JJ, Picard JL. Axillary lymph node metastases in breast cancer: preoperative detection with US.Radiology 1986;158:325–6.
Herrada J, Iyer RB, Atkinson EN, Sneige N, Buzdar AU, Hortobagyi GN. Relative value of physical examination in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma.Clin Cancer Res 1997;3:1565–69.
Tate JJ, Lewis V, Archer T, Guyer PG, Royle GT, Taylor I. Ultrasound detection of axillary lymph node metastases in breast cancer.Eur J Surg Oncol 1989;15:139–41.
Pamilo M, Soiva M, Lavast EM. Real-time ultrasound, axillary mammography, and clinical examination in the detection of axillary lymph node metastases in breast cancer patients.J Ultrasound Med 1989;8:115–20.
De Freitas R, Costa MV, Schneider SV, Nicolau MA, Marussi E. Accuracy of ultrasound and clinical examination in diagnosis of axillary lymph node metastases in breast cancer.Eur J Surg Oncol 1991;17:240–4.
Bonnema J, van Geel AN, van Ooijen B, et al. Ultrasound guided aspiration biopsy for detection of nonpalpable axillary node metastases in breast cancer patients: new diagnostic method.World J Surg 1997;21:270–4.
Fisher B, Redmond C, Fisher ER, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation.N Engl J Med 1985;312:674–81.
Osborne MP, Ormiston N, Harmer OL, Mckinna JA, Baker J, Greening WP. Breast conservation in the treatment of early breast cancer: a 20-year follow-up.Cancer 1984;53:349–55.
Delouche G, Bachelot F, Premont M, Kurtz JM. Conservation treatment of early breast cancer: long term results and complications.Int J Radiat Oncol Biol Phys 1987;13:29–34.
Wazer DE, Erban JK, Robert NJ, et al. Breast conservation in elderly women for clinically negative axillary lymph nodes without axillary dissection.Cancer 1994;74:878–83.
Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer.N Engl J Med 1995;333:1444–55.
McClean RG, Ege GN. Prognostic value of axillary lymphoscintigraphy in breast carcinoma patients.J Nucl Med 1986;27:1116–24.
Tjandra JJ, Sacks NP, Thompson CH, et al. The detection of axillary lymph node metastases from breast cancer by radiolabelled monoclonal antibodies: a prospective study.Br J Cancer 1989;59:296–302.
Avril N, Dose J, Janicke F, et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabelled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.J Natl Cancer Inst 1996;88:1204–9.
Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy.Ann Surg 1995;222:394–401.
Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes.Lancet 1997;349:1864–7.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kuerer, H.M., Newman, L.A., Fornage, B.D. et al. Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer. Annals of Surgical Oncology 5, 673–680 (1998). https://doi.org/10.1007/BF02303476
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02303476